课题基金 / 基金详情

CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET

CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET
临床试验：P3 紫杉醇贝伐珠单抗作为第一线局部复发治疗药物
批准号：
7951359
负责人：
Witold B. Rybka
金额：
$0.32万
依托单位：
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-04-01 至 2010-03-31
来源：
https://reporter.nih.gov/project-details/7951359
关键词：
Clinical ResearchClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantInstitutionPaclitaxelPatientsResearchResearch PersonnelResourcesSourceUnited States National Institutes of Healthbevacizumabmalignant breast neoplasmmeetings

项目摘要

项目成果

Witold B. Rybka的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to compare the effects of paclitaxel in combination with bevacizumab or paclitaxel alone in patients with breast cancer that has spread or reocurred.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION
CLINICAL TRIAL: PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL
P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR METASTATIC BRCA EC
海外基金